8-K filing — EXELIXIS, INC. (EXEL)
Filed: 2026-08-31 AccNo: 0000939767-26-000104 Size: 272 KB Item 8.01: Other Events
Stocks · News reference
Exelixis Lowers FY2026 Sales Guidance from $2.525B-$2.625B to $2.500B-$2.550B vs $2.595B Est
Exelixis (NASDAQ:EXEL) lowers FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.500 billion-$2.550 billion vs $2.595 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Exelixis Announces Appellate Court Affirms Key Part Of 2024 Judgement Of U.S. District Court In Favor Of Co. Against MSN Laboratories; Appellate Court Upholds District Court Decision That Three Patents Are Not Invalid Covering Crystalline Malate Salt Of Cabozantinib
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54
BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and announces Price Target of $54.
Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52
Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers the price target from $56 to $52.